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Abstract
Background: Pancreatic acinar cell carcinoma (PACC), a rare variant of pancreatic malignancy, is generally managed
the same way as pancreatic ductal adenocarcinoma (PDAC). Surgical resection is the gateway to curing it; however,
once it metastasizes (usually to the liver, lungs, lymph nodes, or peritoneal cavity), systemic chemotherapy has been
the only option, but with unfavorable results.
Case presentation: A 67-year-old man with symptoms of loss of appetite and weight underwent surgery for
malignancy of the pancreatic tail extending into the entire pancreas. The pathological diagnosis was PACC
following total pancreatectomy. Twenty-four months after the pancreatectomy, a solitary liver metastasis was
treated by partial hepatectomy, and, subsequently, 4 months later, he presented with melena. Further examination
revealed a type-2 rectal tumor. Histological examination following biopsy revealed it to be rectal metastasis of
PACC, and it was treated by abdominoperineal resection. Subsequently, the patient did not have tumor recurrence
as of 40 months after pancreatectomy.
Conclusions: This is a rare case of PACC presenting with metachronal metastases in the liver and rectum, and we
successfully treated them by surgical resections. Since the malignant behavior of PACC is usually less than that of
PDAC, surgical resection could be an option even for metastatic lesions when the number and extent of
metastases are limited.
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Background
Pancreatic acinar cell carcinoma (PACC) is relatively rare;
it accounts for 1–2% of pancreatic malignancies [1, 2].
The histological presentation of PACC is quite unique. It
is composed of relatively uniform tumor cells arranged in
acinar, glandular, trabecular, and solid structures, without
ductal formation that is seen in pancreatic ductal adeno-
carcinoma (PDAC) [3]. The clinical prognoses of patients
with PACC are usually much better than those of patients
with PDAC, although approximately half the patients with
PACC are metastatic at the time of diagnosis [4].
Despite these differences between PACC and PDAC,
the clinical management is usually same in both. Surgi-
cal resection is the only potentially curative treatment
for primary PACC, and chemotherapy or radiotherapy
has been performed for locally advanced or metastatic
PACC [5]. However, their therapeutic efficacies in meta-
static PACC have not been established due to small sam-
ple sizes [6].
Here, we report a case of PACC with unusual metachro-
nal metastases in the liver and rectum after 24 and
28 months of the initial curative pancreatectomy, respect-
ively. Metastases of PACC are commonly seen in the liver
and lymph nodes, whereas colorectal metastasis is atypical
and extremely rare. We chose surgical resection for both
liver and rectal metastases with satisfactory outcomes.* Correspondence: tatoda@md.tsukuba.ac.jp
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Case presentation
A 67-year-old man was admitted to the hospital with
symptoms of loss of appetite and weight. Computed
tomography (CT) and magnetic resonance imaging
(MRI) revealed a pancreatic mass extending into the en-
tire pancreas, splenic vein, and inferior mesenteric vein
(Fig. 1). The patient underwent total pancreatectomy.
Macroscopically, a whitish tumor measuring 10 cm was
found in the pancreatic tail and body. Microscopically,
eosinophilic tumor cells were found in a trabecular aci-
nar pattern. Immunohistochemical analysis was negative
for synaptophysin, chromogranin A, CD56, and trypsin.
Finally, we diagnosed it as PACC, T3N0M0 (TNM clas-
sification according to the Union for International
Cancer Control). According to the protocol for advanced
PDAC, adjuvant chemotherapy with S-1 (Taiho Pharma-
ceutical, Tokyo, Japan) was administered for 11 months
after pancreatectomy, and, subsequently, it was stopped
due to the side effects (diarrhea, oral mucositis, fatigue,
and hand-foot syndrome). Twenty-four months after the
pancreatectomy, a solitary mass measuring 1.5 cm was
found in segment 7 of the liver on CT (Fig. 2). The pa-
tient underwent posterior liver segmentectomy with a
histopathological diagnosis of liver metastasis of
PACC. Twenty-eight months after the pancreatectomy,
the patient developed melena. Colonoscopy revealed a
type-2 tumor at the lower rectum (1 cm above the
dentate line, Fig. 3a), and biopsy revealed it to be rectal
metastasis of PACC. CT and positron-emission tomog-
raphy (PET) demonstrated the rectal tumor and an en-
larged lymph node near the inferior mesenteric artery
(Fig. 3b, c). The patient underwent laparoscopic abdo-
minoperineal resection. Peritoneal dissemination was
not found intraoperatively. Macroscopically, the tumor
was 4 cm long, created polypoid elevation of its surface,
contained nodular components and ulceration, and pene-
trated the rectal mucosa into the submucosa and muscu-
laris propria (Fig. 4). Histopathology showed severe
nuclear atypia of the tumor cells, and immunohistochemi-
cal analysis using CDX2, cytokeratin (CK)7, CK19, and
CK20 confirmed the same profile as that of the specimen
from pancreatectomy (Fig. 5). One lymph node out of 32
contained metastases. Thus, the pathological diagnosis
was rectal and lymph node metastasis of PACC. All three
surgical operations resulted in no severe postoperative
complications. Periodic radiological examinations showed
no tumor recurrence at 40 months after the pancreatec-
tomy without additional chemotherapy. Our clinical deci-
sion was approved by the cancer board that included
surgeons, oncologists, radiologists, and pathologists at the
University Hospital of Tsukuba. Informed consent was ob-
tained from the patient.
Discussions and conclusions
PACC, a rare pancreatic cancer, demonstrates different
behaviors and outcomes in comparison with PDAC.
PDAC is the most common type of pancreatic cancer
and is fatal in almost all cases. Frequently, it extends
Fig. 1 Episode 1: primary pancreatic tumor. Diffuse pancreatic mass
in a 67-year-old man. Contrast-enhanced computed tomography
(CT, a) scan and magnetic resonance imaging (MRI, b) showed a
hypovascular pancreatic mass located mainly in the pancreatic tail
(arrows) and involving the entire pancreas (arrow head)
Fig. 2 Episode 2: hepatic metastasis. Twenty-four months after the
pancreatectomy. Contrast-enhanced computed tomography (CT)
scan showed a solitary 1.5-cm hypovascular nodule in segment 7
of the liver (arrow)
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and/or metastasizes to the vessels, perineural tissue, ad-
jacent organs, lymph nodes, liver, lungs, bones, and ad-
renals [7–10]. In contrast, though PACC is also invasive,
it is less aggressive than PDAC [4, 11]. Schmidt et al.
compared 865 cases of PACC with 367,999 of PDAC
and demonstrated that the stage-specific 5-year survival
rate in PACC is better than that in PDAC (e.g., PACC
40.2% vs. PDAC 9.8% at stage II) [12]. Wisnoski et al.
showed that the median survival time in PACC was
47 months, whereas it was only 4 months in PDAC [13].
As in PDAC, surgical resection should be performed in
PACC with a goal of achieving R0 margins [12]. For
metastatic PACC, the chemotherapy protocol of PDAC
has been used, which includes gemcitabine, 5-FU, oxali-
platin, CPT-11, and S-1, or their combinations [14–16].
A systematic review by Glazer et al. demonstrated that
the disease control rate of chemotherapy was 55% and
median survival time in metastatic PACC after chemo-
therapy was 17 months [17]. However, the efficacies of
various chemotherapies have not been studied in con-
trolled, prospective studies, and there are no definitive
guidelines for the treatment of metastatic PACC. Add-
itionally, as Abraham et al. demonstrated, PACC shows
different clinicopathological and genetic features from
PDAC [18]. Therefore, strategies other than chemother-
apy may be considered for metastatic PACC.
Resection of metastases in PACC, as performed in this
case, is not routinely performed [17]. We chose resec-
tion of the liver metastases for two reasons. First, liver
metastases are often multiple in PACC [19]; however, in
Fig. 3 Episode 3: rectal metastasis. Twenty-eight months after the pancreatectomy. a Colonoscopy showed type-2 tumor in the lower rectum, which
was located 1 cm above the dentate line. Histopathological examination following biopsy revealed it to be metastasis of PACC. Arrow, rectal tumor;
arrow head, dentate line. b Computed tomography (CT) scan showed that the rectal tumor was 2.6 cm in diameter and slightly enhanced with the
contrast agent (arrow). c Positron-emission tomography (PET) showed abnormal uptake of nuclear agent at the rectal tumor (arrow)
Fig. 4 Gross features of the surgical specimen of the rectal tumor
(a, frontal view). The cross-sectional loupe view demonstrated that
the tumor created polypoid elevation of its surface, contained
nodular components and ulceration, and penetrated the rectal
mucosa into the submucosa and muscularis propria (b)
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this case, it was solitary, slow growing, and relatively
small even 24 months after the primary pancreatec-
tomy. Second, additional chemotherapy was not favor-
able for this patient due to the severe side effects of the
previous treatment with S-1. After resection of hepatic
metastasis, the rectal metastasis including mesorectal
lymph node metastasis was found, and we estimated
that it could be removed completely with additional re-
section, which would also be effective in preventing
rectal bleeding or obstruction. Would these surgical re-
sections be widely applicable to other cases of PACC?
Hartwig et al. surveyed six cases of metastatic PACC
and presented the effectiveness of surgical resection in
these cases with limited metastases [20]. They studied
the long-term survival of patients with synchronous or
metachronous metastatic disease and non-metastatic
disease who underwent resection and found no signifi-
cant differences between the two groups with 2-year
survival rates of 67% and 69%, respectively. We believe
that potentially resectable metastases in PACC can be
treated by surgical resection, as long as the surgery is
associated with low morbidity.
The colon and rectum are quite rare sites of metasta-
ses from pancreatic cancer, as only a few such cases have
been reported [21–23]. As an example, Ogu et al. re-
ported a case of metachronous sigmoid colon metastasis
of PDAC 24 months after pancreatectomy, which was
treated by colectomy [23]. However, to the best of our
knowledge, there are no reports of colorectal metastasis
in PACC. As suggested by earlier studies, we performed
immunohistochemical analysis including testing for CK7
and CK20 to confirm that the rectal tumor showed the
same profiles as those of the primary PACC and that it
was different from other rectal malignancies [23, 24]. It
should be noted that acinar cell carcinoma would pri-
marily occur in the colon and rectum as reported in sev-
eral studies, in which the patients did not have any
pancreatic tumors [25, 26]. In our case, a large invasive
pancreatic tumor had presented 28 months before the
detection of the rectal tumor; therefore, we consider the
rectal tumor as not a primary tumor but rather a metas-
tasis of PACC. The possibility that this rectal tumor was
secondary to peritoneal dissemination was rejected since
the peritoneum including the Douglas pouch was clear,
Fig. 5 Histological examination of the pancreatic tumor (a–f) and rectal tumor (g–l). Relatively uniform tumor cells were found arranged in an
acinar and solid formation. Both specimens showed the same morphological and immunohistochemical pattern. a, g Hematoxylin-eosin stain
(H&E). b, h Magnified H&E image. c, i Negative for CDX2. d, j Positive for CK7. e, k Positive for CK19. f, l Negative for CK20
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and the tumor was located mainly in the muscular and
mucosal parts of the rectal wall while the adventitia was
free from the tumor. We suspected that the colorectal
metastasis might have developed via the hematogenous
pathway due to severe vascular invasion of the primary
pancreatic cancer followed by metastasis of the mesorec-
tal lymph nodes; however, the true mechanism of rectal
metastasis could not be demonstrated.
We presented a rare case of metachronous hepatic
and rectal metastases of PACC treated with surgical re-
section. Our case indicates that aggressive and curative
surgery can be an option in metastatic PACC. The thera-
peutic strategy against metastases from “less invasive”
PACC should include surgical resection in addition to
chemotherapy to improve the prognosis.
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